PeptidePreclinical
Retatrutide
Also known as: LY3437943
Triple GLP-1/GIP/Glucagon Agonist | Weight Loss & Diabetes
Overview
Novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase II trials demonstrated 24.2% weight loss at 48 weeks—the highest recorded for obesity medications.
Key benefits
- Superior weight loss (24.2% at 48 weeks)
- Improved glycemic control (HbA1c reduction up to 2.16%)
- Enhanced cardiovascular benefits
- Hepatic fat reduction (up to 82%)
- Triple mechanism addresses obesity through multiple pathways
Mechanism of action
Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation.
Molecular data
- Type
- Triple GLP-1/GIP/glucagon agonist
- Half-life
- ~6 days
Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Type 2 Diabetes
Cardiovascular/Metabolic
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.5mg | Once weekly | — |
| — | 1mg | Once weekly | — |
| — | 2mg | Once weekly | — |
| — | 4mg | Once weekly | — |
| — | 8mg | Once weekly | — |
| — | 12mg | Once weekly | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
- Heart rate increases—common especially in first 24 weeks
- Appetite suppression
- Mild dehydration
Contraindications
- Personal or family history of medullary thyroid carcinoma
- MEN2 syndrome
- Severe renal impairment
Monitoring
- Cardiovascular status (especially heart rate)
- Blood glucose if diabetic
- Weight loss rate
- Signs of pancreatitis
- Gastrointestinal tolerability
References
Primary literature and clinical-trial data informing this entry.